The first major depression treatment to hit the U.S. market in decades may be a new option for patients who fail to respond to existing therapies, but a preliminary analysis shows the price of the medicine would have to be shaved by 25 percent in order to be cost effective.

Known as esketamine and marketed as Spravato, the nasal spray was developed by Johnson & Johnson (JNJ), which set a list price of $590 to $885 per treatment session, depending on dosing and number of sessions, which can vary by patient. The initial month of therapy can cost from $4,720 to $6,785, while subsequent treatment can cost $2,360 to $3,540. Put another way, the annual tab might run from $33,000 to about $49,200.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • The first sentence sums up the problems with ICER’s conclusion: “The first major depression treatment to hit the U.S. market in decades…”

    Also, ICER used the WAC (list) price, thereby ignoring Medicaid rebates and 340B discounts. See page 65 of ICER report.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy